Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 9/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.45 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7797941 | 0.87 | HTR2A (0.36) | HTR2ATAAR1PDE4APDE4BPDE4C | |
| SCHEMBL4696548 | 0.86 | HTR2A (0.52) | HTR2ATAAR1PDE4APDE4BPDE4C | |
| SCHEMBL5355957 | 0.80 | PDE4A (0.46) | HTR2ATAAR1PDE4APDE4BPDE4C | |
| SCHEMBL17366526 | 0.80 | PDE4A (0.52) | HTR2ATAAR1PDE4APDE4BPDE4C | |
| SCHEMBL24765332 | 0.78 | HTR2A (0.61) | HTR2ATAAR1PDE4APDE4BPDE4C | |
| SCHEMBL29966236 | 0.78 | HTR2A (0.61) | HTR2ATAAR1PDE4APDE4BPDE4C | |
| SCHEMBL14948494 | 0.74 | HTR2A (0.52) | HTR2ATAAR1PDE4APDE4BPDE4C | |
| SCHEMBL7797940 | 0.74 | HTR2A (0.38) | HTR2ATAAR1HTR2CKDM4EALDH1A1 | |
| SCHEMBL16117914 | 0.74 | PDE4A (0.46) | HTR2ATAAR1PDE4APDE4BPDE4C | |
| SCHEMBL1571513 | 0.74 | HTR2A (0.47) | HTR2ATAAR1PDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010025045-A1 | Substituted isoquinoline derivatives and their use as anticonvulsants | SMITHKLINE BEECHAM P.L.C. | 2001-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010025045-A1 | Substituted isoquinoline derivatives and their use as anticonvulsants | INA, GRIN2C, GRIN2A | HTR2A 315/4885TAAR1 1633/4885PDE4A 898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.